Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Russell, J. S.
Right arrow Articles by Tofilon, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Russell, J. S.
Right arrow Articles by Tofilon, P. J.
Clinical Cancer Research Vol. 9, 3749-3755, September 1, 2003
© 2003 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Enhanced Cell Killing Induced by the Combination of Radiation and the Heat Shock Protein 90 Inhibitor 17-Allylamino-17- Demethoxygeldanamycin

A Multitarget Approach to Radiosensitization

Jeffery S. Russell, William Burgan, Kelli A. Oswald, Kevin Camphausen and Philip J. Tofilon1

Molecular Radiation Therapeutics Branch [J. S. R., W. B., K. A. O., P. J. T.], Radiation Oncology Branch [K. C.], Radiation Oncology Science Program, National Cancer Institute, Bethesda, Maryland 20892

Purpose: Current strategies for tumor cell radiosensitization focus on a target-based approach. However, the radioresponse of a tumor cell is influenced by a wide variety of signaling molecules existing in a number of different survival pathways. Therefore, in an attempt to increase the probability and/or degree of radiosensitization, we have begun to investigate a multitarget approach using the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG).

Experimental Design: The effect of 17AAG on the levels of three proteins (Raf-1, ErbB2, and Akt) previously implicated in the regulation of radiosensitivity was determined in four human tumor cell lines. Tumor cell survival after exposure to corresponding concentrations of 17AAG combined with clinically relevant doses of X-rays was then evaluated using a clonogenic assay. The radiosensitivity of a nonimmortalized, normal fibroblast cell line was also determined after exposure to 17AAG.

Results: Exposure to nanomolar concentrations of 17AAG reduced the levels of the three radiosensitivity-associated proteins in a cell type manner. Using corresponding concentrations, 17AAG enhanced the radiosensitivity of each of the tumor cell lines with enhancement factors ranging from 1.3 to 1.7. The enhancement appeared to be related to the number of radioresponse-regulatory proteins affected. In contrast to the tumor cell lines, 17AAG had no effect on the radiosensitivity of a normal, nonimmortalized human fibroblast cell line.

Conclusions: These data suggest that heat shock protein 90 may be an appropriate target for selectively enhancing the radiosensitivity of tumor cells over normal cells. Furthermore, they illustrate the potential of a multitarget approach to radiosensitization.




This article has been cited by other articles:


Home page
Cancer Res.Home page
N. Gaspar, S. Y. Sharp, S. Pacey, C. Jones, M. Walton, G. Vassal, S. Eccles, A. Pearson, and P. Workman
Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells
Cancer Res., March 1, 2009; 69(5): 1966 - 1975.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W.-Y. Kim, S. H. Oh, J.-K. Woo, W. K. Hong, and H.-Y. Lee
Targeting Heat Shock Protein 90 Overrides the Resistance of Lung Cancer Cells by Blocking Radiation-Induced Stabilization of Hypoxia-Inducible Factor-1{alpha}
Cancer Res., February 15, 2009; 69(4): 1624 - 1632.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
C. M.-E. Sauvageot, J. L. Weatherbee, S. Kesari, S. E. Winters, J. Barnes, J. Dellagatta, N. R. Ramakrishna, C. D. Stiles, A. L.-J. Kung, M. W. Kieran, et al.
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
Neuro-oncol, January 1, 2009; 11(2): 109 - 121.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Fukuyo, M. Inoue, T. Nakajima, R. Higashikubo, N. T. Horikoshi, C. Hunt, A. Usheva, M. L. Freeman, and N. Horikoshi
Oxidative Stress Plays a Critical Role in Inactivating Mutant BRAF by Geldanamycin Derivatives
Cancer Res., August 1, 2008; 68(15): 6324 - 6330.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Camphausen and P. J. Tofilon
Inhibition of Hsp90: A Multitarget Approach to Radiosensitization
Clin. Cancer Res., August 1, 2007; 13(15): 4326 - 4330.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Ferrario, N. Rucker, S. Wong, M. Luna, and C. J. Gomer
Survivin, a Member of the Inhibitor of Apoptosis Family, Is Induced by Photodynamic Therapy and Is a Target for Improving Treatment Response
Cancer Res., May 15, 2007; 67(10): 4989 - 4995.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Dote, W. E. Burgan, K. Camphausen, and P. J. Tofilon
Inhibition of hsp90 compromises the DNA damage response to radiation.
Cancer Res., September 15, 2006; 66(18): 9211 - 9220.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Dote, D. Cerna, W. E. Burgan, K. Camphausen, and P. J. Tofilon
ErbB3 Expression Predicts Tumor Cell Radiosensitization Induced by Hsp90 Inhibition
Cancer Res., August 1, 2005; 65(15): 6967 - 6975.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. E. A. Bull, H. Dote, K. J. Brady, W. E. Burgan, D. J. Carter, M. A. Cerra, K. A. Oswald, M. G. Hollingshead, K. Camphausen, and P. J. Tofilon
Enhanced Tumor Cell Radiosensitivity and Abrogation of G2 and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin
Clin. Cancer Res., December 1, 2004; 10(23): 8077 - 8084.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.